Login to Your Account

Oxford Signs Potential $1B ADC Alliance with Menarini

By Nuala Moran
Staff Writer

Tuesday, October 30, 2012
LONDON – Oxford BioTherapeutics Ltd. (OBT) has landed a "transformational" deal with Menarini, in which the Italian pharma company is to invest €800 million (US$1 billion) in a portfolio of five antibody and antibody-conjugate drugs discovered by OBT.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription